NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice

Spinal muscular atrophy (SMA) is a neuromuscular disease causing the most frequent genetic childhood lethality. Recently, nusinersen, an antisense oligonucleotide (ASO) that corrects SMN2 splicing and thereby increases full-length SMN protein, has been approved by the FDA and EMA for SMA therapy. Ho...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Am J Hum Genet
Glavni autori: Torres-Benito, Laura, Schneider, Svenja, Rombo, Roman, Ling, Karen K., Grysko, Vanessa, Upadhyay, Aaradhita, Kononenko, Natalia L., Rigo, Frank, Bennett, C. Frank, Wirth, Brunhilde
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2019
Teme:
Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6612520/
https://ncbi.nlm.nih.gov/pubmed/31230718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajhg.2019.05.008
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items